NEW YORK, October 28, 2016 /PRNewswire/ --
Stock-Callers.com has initiated coverage on the following Biotechnology companies: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Pain Therapeutics Inc. (NASDAQ: PTIE), CoLucid Pharmaceuticals Inc. (NASDAQ: CLCD), and CEL-SCI Corp. (NYSE MKT: CVM). These equities belong to the Healthcare sector which remained higher in late trade on Thursday, October 27, 2016, with the NYSE Health Care Index rising 0.3%, and shares of health care companies in the S&P 500 up more than 0.5% as a group. Learn more about these stocks by downloading their free report at:
Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc.'s stock finished Thursday's session 0.53% higher at $3.77 with a total trading volume of 533,510 shares. Shares of the Company, which develops and commercializes oncology and hematology drug products, are trading below their 50-day moving average by 22.56%. The stock has a Relative Strength Index (RSI) of 29.19.
On October 27th, 2016, Spectrum Pharmaceuticals announced it will host a teleconference and webcast with management discussing Q3 2016 financial results, providing an update on the Company's business, and talking about expectations for the future on November 3rd, 2016 at 4:30 p.m. ET. The free research report on SPPI is available at:
On Thursday, shares in Austin, Texas-based Pain Therapeutics Inc. ended the session at $0.61, down 2.96%. The stock recorded a trading volume of 276,006 shares. The Company's shares are trading 64.71% below their 50-day moving average. Moreover, shares of Pain Therapeutics, which develops novel drugs in the US, have an RSI of 24.64.
On October 20th, 2016, Pain Therapeutics reported that net loss in Q3 2016 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2015 of $3.7 million, or $0.08 per share. At September 30, 2016, cash and investments were $21.8 million compared to $24.6 million at June 30, 2016. The Company has no debt. The complimentary report on PTIE can be downloaded at:
Cambridge, Massachusetts headquartered CoLucid Pharmaceuticals Inc.'s stock ended yesterday's session 2.05% lower at $31.98 with a total trading volume of 113,556 shares. The Company's shares have surged 267.59% in the previous three months and 282.08% on an YTD basis. The stock is trading 22.93% above its 50-day moving average and 173.42% above its 200-day moving average. Additionally, shares of CoLucid Pharmaceuticals, which develops small molecules for the acute treatment of migraine, have an RSI of 51.35.
On October 5th, 2016, CoLucid Pharmaceuticals provided additional data regarding onset of action demonstrated as soon as 30 minutes after dosing for 100 mg and 200 mg of lasmiditan from its Phase 3 pivotal trial evaluating lasmiditan, the SAMURAI study. Data from the SAMURAI study were collected using electronic diaries during the treated attack. Beginning pre-dose, patients indicated their degree of headache pain on a 4-point scale: 0, no pain; 1, mild pain; 2, moderate pain; or 3, severe pain. Migraine headache relief was defined as moderate or severe headache pain at baseline reduced to mild or no headache pain at the time point assessment. Lasmiditan was effective at both the 100 mg dose and the 200 mg dose in relieving migraine headache pain as soon as 30 minutes (p ≤ 0.004) as compared to placebo.
On October 24th, 2016, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $30 a share to $40 a share. Visit us today and download our complete research report on CLCD for free at:
At the close on Thursday, shares in Vienna, Virginia headquartered CEL-SCI Corp. recorded a trading volume of 271,824 shares. The stock finished flat at $0.23. The Company's shares are trading below their 50-day moving average by 36.67%. Furthermore, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 35.69.
On October 21st, 2016, CEL-SCI announced that it has received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA), regarding its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer. CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted. Get free access to your technical report on CVM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA